DM
SRPT icon

Deerfield Management’s Sarepta Therapeutics SRPT Stock Holding History

Deerfield Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-100,000
Closed -$4.72M – 122
2013
Q3 		$4.72M Buy
+100,000
New +$3.85M 0.22% 81

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management's SRPT Position: Q1 2022 in Review

Deerfield Management sold out of Sarepta Therapeutics (SRPT) in Q1 2022, closing a stake of 141,000 shares — an estimated $12.7M sold.

Deerfield Management first reported a position in SRPT in Q2 2018 and held it in 9 quarters. The position peaked at $47.8M in Q3 2018. 328 funds tracked by Wall St. Rank hold SRPT as of Q1 2022.

  • Deerfield Management reported no remaining Sarepta Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Deerfield Management sold 141,000 Sarepta Therapeutics shares in Q1 2022, an estimated $12.7M.
  • Deerfield Management first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 9 quarters.
  • Deerfield Management's Sarepta Therapeutics position peaked at $47.8M in Q3 2018.
  • 328 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2022.

Based on Deerfield Management's 13F filing for Q1 2022, filed 16 May 2022.